Is CVS a good stock to buy?
CVS Health Corp. · end-of-day data as of Nov 13, 2026
- PT$110.28 +23.4%
- ConsensusBuy · 28
- P/E vs own-67.1%
- P/E vs sector-67.7%
- FCF yield+13.6%
- Insiders$2M
- News
- MA20×50Golden 3d ago
- MACD0.18
- Sector▲ +15.9%
- Earnings in88d
- P/E10.4x
- RSI51
- Support-1.1%
- Resistance+3.1%
- Off 52w high-19.3%
- Volume0.7x
- Bollingerlower half
- 52w range$70–$111
- ATR+3.4%
- Off ATH-21.4%
- MAs2 of 4
- Trendbearish
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is CVS Health a good stock to buy?
CVS Health is strong on 2 of the 5 questions about the business; weak on economics. The price is low: 10.4 times its earnings, below its 3-year median of 16.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage some edge
- Economics thin margins
- Execution delivers
- Fragility sturdy
- Price below its usual
CVS sales growth revenue growth
+8%a year, for the last 3 yearsCVS Health's sales grew 8% a year for 3 years, to $402B in fiscal 2025.
CVS analysts' forecast revenue estimates
+5%the sales they expect next fiscal year, on the lastAnalysts expect CVS Health's sales to grow 5% to $421B in fiscal 2026 (16 analysts).
CVS return on capital ROIC
pretickt analysis10%earned before tax on the money invested in itCVS Health earned 10% before tax on the capital invested in it in the 12 months to Sep 30, 2026; UnitedHealth 16%, Cigna 14%, Elevance Health 11% and Humana 8%.
CVS margin on each sale gross margin
14%left after making the productCVS Health kept 14% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 18%.
CVS margin after costs profit margin
4%of sales left after running the businessCVS Health's operating margin was 4% in the 12 months to Sep 30, 2026, against 2% in fiscal 2022.
CVS cash generated free cash flow
$15.57Bcash left after investing, last 12 monthsCVS Health generated $15.57B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
CVS earnings vs estimates
8 of 8quarters above the analysts' estimateCVS Health beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 4, 2026.
CVS insider selling
-$344Msold, net, by its executives in 12 monthsCVS Health's executives and directors sold a net $344M of shares in the 12 months to Nov 13, 2026 ($346M sold, $2M bought).
CVS number of employees
0%about as many people as a year beforeCVS Health had 300,000 employees at the end of fiscal 2025, about as many as a year before.
CVS CEO pay
$21.21Mfor fiscal 2025, 68% of it in stock and optionsCVS Health paid its CEO $21.21M for fiscal 2025, 68% of it in stock and options.
CVS financial health Altman Z-score
2.5Altman Z-score, safe above 3CVS Health's Altman Z-score is 2.5 (Nov 13, 2026), between 1.8 and 3, the grey zone.
CVS quality checks Piotroski score
8 of 9checks passedCVS Health passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on new shares.
CVS biggest customers
20%of sales from its biggest customerU.S. federal government made 20% of CVS Health's sales in fiscal 2025.
CVS in past recessions
pretickt analysis+5%its sales in the worst oneCVS Health's sales grew through each of the last 2 US recessions (2008–09 and 2020).
CVS price vs profit P/E ratio
10.4×a year's earningsCVS Health's P/E ratio is 10.4 (Nov 13, 2026), below its 3-year median of 16.1.
CVS price vs competitors
pretickt analysis10.4×a year's earnings, against its competitorsInvestors pay 10.4 times CVS Health's earnings (Nov 13, 2026), less than for Humana (43.8), UnitedHealth (23.3), Elevance Health (18.3) or Cigna (13.1).
CVS analysts' target price target
+23%to their average targetAnalysts' average price target for CVS Health is $110, 23% above the Nov 13, 2026 close of $89.35.
CVS growth priced in fair value
pretickt analysis-7%a year, for ten years, and still worth the priceAt $89.35 a share, CVS Health's free cash flow could shrink about 7% a year for ten years and still be worth the price (Nov 13, 2026).
What is CVS Health's P/E ratio?
CVS Health's P/E ratio is 10.4 (Nov 13, 2026), below its 3-year median of 16.1. Investors pay 10.4 times CVS Health's earnings (Nov 13, 2026), less than for Humana (43.8), UnitedHealth (23.3), Elevance Health (18.3) or Cigna (13.1).
Who are CVS Health's biggest competitors?
pretickt compares CVS Health with Elevance Health, Cigna, Humana and UnitedHealth. CVS Health's sales grew 7% in the 12 months to Sep 30, 2026, faster than Elevance Health (+4%) and UnitedHealth (+3%), slower than Humana (+22%) and Cigna (+7%).
Is CVS Health profitable?
CVS Health's operating margin was 4% in the 12 months to Sep 30, 2026, against 2% in fiscal 2022. CVS Health generated $15.57B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
Are insiders selling CVS Health stock?
CVS Health's executives and directors sold a net $344M of shares in the 12 months to Nov 13, 2026 ($346M sold, $2M bought).
Who owns CVS Health stock?
2,182 institutions hold 90% of CVS Health's shares (Jun 30, 2026); Vanguard and Capital Group added shares that quarter, BlackRock sold some.
How many employees does CVS Health have?
CVS Health had 300,000 employees at the end of fiscal 2025, about as many as a year before.
Who are CVS Health's biggest customers?
U.S. federal government made 20% of CVS Health's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.